Atea (AVIR) CCO granted 119,520 stock options and adds shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Atea Pharmaceuticals Chief Commercial Officer John Vavricka reported several equity transactions in the company’s stock. On January 31, 2026, he acquired 42,083 shares of common stock through the vesting and settlement of restricted stock units.
To cover tax obligations, 11,570 shares of common stock were withheld at a price of $4.24 per share, leaving him with 82,594 directly held shares. He also holds 82,508 shares indirectly as trustee of the John F. Vavricka Deed of Trust.
On the same date, Vavricka received a new grant of 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments after January 31, 2026 and will be fully vested by January 31, 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
42,083 shares exercised/converted
Mixed
6 txns
Insider
Vavricka John
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 33,333 | $0.00 | -- |
| Exercise | Restricted Stock Units | 8,750 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 119,520 | $0.00 | -- |
| Exercise | Common Stock | 42,083 | $0.00 | -- |
| Tax Withholding | Common Stock | 11,570 | $4.24 | $49K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Stock Option (Right to Buy) — 119,520 shares (Direct);
Common Stock — 94,164 shares (Direct);
Common Stock — 82,508 shares (Indirect, Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.
FAQ
What insider transactions did Atea Pharmaceuticals (AVIR) report for John Vavricka?
Atea’s Chief Commercial Officer John Vavricka acquired 42,083 common shares from RSU settlements and had 11,570 shares withheld for taxes at $4.24. He also received 119,520 new stock options and now holds common stock both directly and through a personal trust.
What stock options did Atea’s CCO receive according to this Form 4?
The filing shows Vavricka was granted 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments following January 31, 2026, and will be fully vested by January 31, 2030, aligning incentives over a multi-year period.
What happened to John Vavricka’s restricted stock units in Atea (AVIR)?
Previously granted RSUs, including 33,333 time-based units and 8,750 performance-based units, vested and were settled into common stock on January 31, 2026. After these conversions, the reported RSU balances are zero, meaning all those specific awards have fully vested.
How do the new Atea stock options for Vavricka vest over time?
The 119,520 stock options vest in forty-eight equal monthly installments after January 31, 2026. According to the filing, this means the grant becomes fully exercisable on January 31, 2030, creating a long-term incentive structure for Atea’s Chief Commercial Officer.